⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

Official Title: Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation

Study ID: NCT02686346

Conditions

Hodgkin Disease

Study Description

Brief Summary: This study is designed as a phase Ib/II trial. The first part (phase Ib) is a dose escalation design to explore the safety and assess the recommended phase 2 dose of Brentuximab Vedotin in Hodgkin lymphoma patients treated with ICE regimen. The second part, depending on the selected dose after the completion of phase Ib part of the study, will further explore safety in addition to efficacy of the recommended dose of Brentuximab Vedotin in a selected population of patients treated with ICE with Hodgkin lymphoma.

Detailed Description: PHASE I: 3 cycles of Brentuximab Vedotin ICE every 3 weeks and one cycle of Brentuximab Vedotin alone at the doses described below. Cohorts of between three and six evaluable patients will be recruited at each dose level. Dose escalation rules: Treat 3 patients at level K 1. If 0 patients experience dose-limiting toxicity (DLT), escalate to dose K+1 2. If 2 or more patients experience DLT, de-escalate to level K-1 3. If 1 patient experiences DLT, treat 3 more patients at dose level K A. If 1 of 6 experiences DLT, escalate to dose level K+1 B. If 2 or more of 6 experiences DLT, de-escalate to level K-1 Dose escalation will begin at level K. Level K: Brentuximab Vedotin: 1.2 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2) Level K -1: Brentuximab Vedotin: 0.8 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2) Level K +1: Brentuximab Vedotin: 1.8 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2) Dose finding rule: Provisional dose levels are listed in previous tables. Dose-escalation will continue until Maximal Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) is reached or the full doses of BV and ICE are delivered without DLT PHASE II: 3 cycles of Brentuximab Vedotin + ICE every 3 weeks and one cycle Brentuximab Vedotin alone. The recommended dose of BV and ICE will be determined by the phase I Brentuximab Vedotin: MTD mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2) The recommended dose of BV and ICE will be determined by the phase I.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Clinique Universitaire Saint-Luc, Bruxelles, , Belgium

CHU Dinant Godinne, Yvoir, , Belgium

Institut d'Hématologie de Basse Normandie - CHU Côte de Nacre, Caen, , France

APHP-Hôpital Henri Mondor, Créteil, , France

CHU de Dijon - Hôpital le Bocage, Dijon, , France

CHRU Lille - Hôpital Claude Huriez, Lille, , France

Centre Léon Bérard, Lyon, , France

CHU Saint Eloi, Montpellier, , France

CHU De Nantes, Nantes, , France

APHP - Hôpital Saint Louis, PARIS Cedex 10, , France

Hôpital Necker, Paris, , France

CHU Lyon Sud, Pierre Bénite Cedex, , France

CHU de Poitiers - Hôpital de La Milétrie, Poitiers, , France

CHU De Rennes, Rennes, , France

Centre Henri Becquerel, Rouen, , France

CHU De Strasbourg, Strasbourg, , France

IUCT Toulouse, Toulouse, , France

CHU De Nancy - Hôpital Brabois, Vandœuvre-lès-Nancy, , France

Institut Gustave Roussy, VILLEJUIF Cedex, , France

Contact Details

Name: Pauline Brice, MD

Affiliation: Lymphoma Study Association

Role: PRINCIPAL_INVESTIGATOR

Name: Aspasia Stamatoullas Bastard, MD

Affiliation: Lymphoma Study Association

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: